145 related articles for article (PubMed ID: 37001283)
21. Defibrotide Shows Efficacy in the Prevention of Sinusoidal Obstruction Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Study.
Chalandon Y; Mamez AC; Giannotti F; Beauverd Y; Dantin C; Mahne E; Mappoura M; Bernard F; de Ramon Ortiz C; Stephan C; Morin S; Ansari M; Simonetta F; Masouridi-Levrat S
Transplant Cell Ther; 2022 Nov; 28(11):765.e1-765.e9. PubMed ID: 35953029
[TBL] [Abstract][Full Text] [Related]
22. Final results from a defibrotide treatment-IND study for patients with hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Kernan NA; Grupp S; Smith AR; Arai S; Triplett B; Antin JH; Lehmann L; Shore T; Ho VT; Bunin N; Iacobelli M; Liang W; Hume R; Tappe W; Soiffer R; Richardson P
Br J Haematol; 2018 Jun; 181(6):816-827. PubMed ID: 29767845
[TBL] [Abstract][Full Text] [Related]
23. The budget impact and cost-effectiveness of defibrotide for treatment of veno-occlusive disease with multi-organ dysfunction in patients post-hematopoietic stem cell transplant.
Veenstra DL; Guzauskas GF; Villa KF; Boudreau DM
J Med Econ; 2017 May; 20(5):453-463. PubMed ID: 28008770
[TBL] [Abstract][Full Text] [Related]
24. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
25. Hepatic veno-occlusive disease in pediatric stem cell transplantation: impact of pre-emptive antithrombin III replacement and combined antithrombin III/defibrotide therapy.
Haussmann U; Fischer J; Eber S; Scherer F; Seger R; Gungor T
Haematologica; 2006 Jun; 91(6):795-800. PubMed ID: 16769582
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness analysis of defibrotide in the treatment of patients with severe veno-occlusive disease/sinusoidal obstructive syndrome with multiorgan dysfunction following hematopoietic cell transplantation in Spain.
Carcedo Rodriguez D; Artola Urain T; Chinea Rodriguez A; García Torres E; González Vicent M; Gutiérrez García G; Regueiro García A; Calvo Hidalgo M; Villacampa A
J Med Econ; 2021; 24(1):628-636. PubMed ID: 33858278
[TBL] [Abstract][Full Text] [Related]
27. Synergistic interactions between interferon-gamma and TRAIL modulate c-FLIP in endothelial cells, mediating their lineage-specific sensitivity to thrombotic thrombocytopenic purpura plasma-associated apoptosis.
Stefanescu R; Bassett D; Modarresi R; Santiago F; Fakruddin M; Laurence J
Blood; 2008 Jul; 112(2):340-9. PubMed ID: 18339897
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of low dose and short duration defibrotide prophylaxis for hepatic veno-occlusive disease after autologous haematopoietic stem cell transplantation.
Roh YY; Hahn SM; Kim HS; Ahn WK; Han JH; Kwon S; Lyu CJ; Han JW
Bone Marrow Transplant; 2021 Feb; 56(2):411-418. PubMed ID: 32839533
[TBL] [Abstract][Full Text] [Related]
29. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
30. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
Nauffal M; Kim HT; Richardson PG; Soiffer RJ; Antin JH; Cutler C; Nikiforow S; Gooptu M; Koreth J; Romee R; Ho VT
Blood Adv; 2022 Jan; 6(1):181-188. PubMed ID: 34666352
[TBL] [Abstract][Full Text] [Related]
31. Defibrotide for the treatment of severe hepatic veno-occlusive disease and multiorgan failure after stem cell transplantation: a multicenter, randomized, dose-finding trial.
Richardson PG; Soiffer RJ; Antin JH; Uno H; Jin Z; Kurtzberg J; Martin PL; Steinbach G; Murray KF; Vogelsang GB; Chen AR; Krishnan A; Kernan NA; Avigan DE; Spitzer TR; Shulman HM; Di Salvo DN; Revta C; Warren D; Momtaz P; Bradwin G; Wei LJ; Iacobelli M; McDonald GB; Guinan EC
Biol Blood Marrow Transplant; 2010 Jul; 16(7):1005-17. PubMed ID: 20167278
[TBL] [Abstract][Full Text] [Related]
32. Defibrotide in hematopoietic stem cell transplantation: A multicenter survey study of the Spanish Hematopoietic Stem Cell Transplantation Group (GETH).
González Vicent M; Díaz de Heredia C; González de Pablo J; Molina B; Regueiro A; Pérez Martinez A; Palomo P; López Corral L; García E; Fernández JM; Pérez A; Jiménez MJ; Guerreiro M; Vallejo C; Gallardo AI; López O; Benito A; Marsal J; Duarte M; Bento L; Badell I; Pedraza A; Jiménez Ubieto A; González P; Gómez Centurión I; Costilla L; Beléndez C; Esquirol A; Espigado I; Lavilla E; Díaz MÁ
Eur J Haematol; 2021 Jun; 106(6):842-850. PubMed ID: 33713387
[TBL] [Abstract][Full Text] [Related]
33. Thrombotic thrombocytopenic purpura and sporadic hemolytic-uremic syndrome plasmas induce apoptosis in restricted lineages of human microvascular endothelial cells.
Mitra D; Jaffe EA; Weksler B; Hajjar KA; Soderland C; Laurence J
Blood; 1997 Feb; 89(4):1224-34. PubMed ID: 9028945
[TBL] [Abstract][Full Text] [Related]
34. Low, fixed dose defibrotide in management of hepatic veno-occlusive disease post stem cell transplantation.
Bagal B; Chandrasekharan A; Chougle A; Khattry N
Hematol Oncol Stem Cell Ther; 2018 Mar; 11(1):47-51. PubMed ID: 28460209
[TBL] [Abstract][Full Text] [Related]
35. Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.
Corbacioglu S; Kernan N; Lehmann L; Brochstein J; Revta C; Grupp S; Martin P; Richardson PG
Expert Rev Hematol; 2012 Jun; 5(3):291-302. PubMed ID: 22780209
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and Safety of Defibrotide for the Treatment of Hepatic Veno-Occlusive Disease after Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis.
Yang L; Qi J; Pan T; You T; Ruan C; Han Y
Semin Thromb Hemost; 2019 Nov; 45(8):767-777. PubMed ID: 31627217
[TBL] [Abstract][Full Text] [Related]
37. A Systematic Review and Meta-Analysis of Studies of Defibrotide Prophylaxis for Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Corbacioglu S; Topaloglu O; Aggarwal S
Clin Drug Investig; 2022 Jun; 42(6):465-476. PubMed ID: 35594010
[TBL] [Abstract][Full Text] [Related]
38. Thrombotic microangiopathies: thrombotic thrombocytopenic purpura / hemolytic uremic syndrome.
Polito MG; Kirsztajn GM
J Bras Nefrol; 2010; 32(3):303-15. PubMed ID: 21103695
[TBL] [Abstract][Full Text] [Related]
39. Coronavirus Disease 2019-Associated Thrombotic Microangiopathy: Literature Review.
Malgaj Vrečko M; Aleš Rigler A; Večerić-Haler Ž
Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232608
[TBL] [Abstract][Full Text] [Related]
40. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.
Corbacioglu S; Cesaro S; Faraci M; Valteau-Couanet D; Gruhn B; Rovelli A; Boelens JJ; Hewitt A; Schrum J; Schulz AS; Müller I; Stein J; Wynn R; Greil J; Sykora KW; Matthes-Martin S; Führer M; O'Meara A; Toporski J; Sedlacek P; Schlegel PG; Ehlert K; Fasth A; Winiarski J; Arvidson J; Mauz-Körholz C; Ozsahin H; Schrauder A; Bader P; Massaro J; D'Agostino R; Hoyle M; Iacobelli M; Debatin KM; Peters C; Dini G
Lancet; 2012 Apr; 379(9823):1301-9. PubMed ID: 22364685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]